CYT387

Sierra Oncology LLC - a GSK company · Phase 1 active Small molecule

At a glance

Generic name	CYT387
Also known as	Momelotinib
Sponsor	Sierra Oncology LLC - a GSK company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CYT387 CI brief — competitive landscape report
CYT387 updates RSS · CI watch RSS
Sierra Oncology LLC - a GSK company portfolio CI